Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

24.0%

12 terminated/withdrawn out of 50 trials

Success Rate

69.2%

-17.3% vs industry average

Late-Stage Pipeline

44%

22 trials in Phase 3/4

Results Transparency

107%

29 of 27 completed trials have results

Key Signals

6 recruiting29 with results9 terminated

Enrollment Performance

Analytics

Phase 2

23(48.9%)

Phase 3

19(40.4%)

Phase 4

3(6.4%)

Early Phase 1

1(2.1%)

Phase 1

1(2.1%)

47Total

Phase 2(23)

Phase 3(19)

Phase 4(3)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (50)

Showing 20 of 50 trials

NCT07284667Phase 2Recruiting

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Role: lead

NCT06194799Phase 3Enrolling By Invitation

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Role: lead

NCT07029581Phase 2Recruiting

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Role: lead

NCT07095465Phase 3Enrolling By Invitation

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Role: lead

NCT06159673Phase 2Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

Role: lead

NCT05999240Phase 2Recruiting

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Role: collaborator

NCT03947216Phase 2Completed

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Role: collaborator

NCT06420297Phase 3Enrolling By Invitation

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Role: lead

NCT05555615Phase 2Terminated

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Role: lead

NCT06173531Phase 3Active Not Recruiting

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Role: lead

NCT03121586Phase 3Terminated

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Role: lead

NCT05523895Phase 2Completed

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Role: lead

NCT04531982Phase 3Completed

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Role: lead

NCT05357612Phase 4Recruiting

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Role: collaborator

NCT05895513Phase 2Recruiting

Pimavanserin and Aggression and Social Cognition.

Role: collaborator

NCT00490516Phase 2Completed

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Role: lead

NCT04292223Phase 4Completed

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Role: lead

NCT05008835Phase 2Terminated

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Role: lead

NCT03575052Phase 3Completed

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Role: lead

NCT03623321Phase 3Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Role: lead